⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273257 | 0.81 | CA1 (0.36) | — | |
| Sulfurous Acid SCHEMBL197348 | 0.78 | CA1 (0.43) | — | |
| SCHEMBL8930998 | 0.75 | CYP2C19 (0.35) | — | |
| SCHEMBL186291 | 0.75 | CA1 (0.31) | — | |
| SCHEMBL2835119 | 0.75 | CA1 (0.31) | — | |
| Sulfurous Acid SCHEMBL29196101 | 0.73 | CA1 (0.38) | — | |
| SCHEMBL127455 | 0.73 | — | — | |
| SCHEMBL4139054 | 0.71 | — | — | |
| SCHEMBL778688 | 0.71 | — | — | |
| SCHEMBL16549754 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| EP-1883645-B1 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC (CA) | 2011-06-29 | — | — | EP | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7498355-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2009-03-03 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| EP-1883645-A4 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1883645-A1 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | Antibe Therapeutics Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2006125293-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270635-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2006-11-30 | — | — | US | disclosed |
| WO-2006125295-A1 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2006-11-30 | — | — | WO | disclosed |